HbA1c ( baseline : dapagliflozin 8.08 % [ 65 mmol/mol ] ; placebo 8.24 % [ 67 mmol/mol ] ) and fasting plasma glucose ( baseline : dapagliflozin 167.4 mg/dL [ 9.29 mmol/L ] ; placebo 180.5 mg/dL [ 10.02 mmol/L ] ) significantly improved from baseline with dapagliflozin ( placebo-subtracted change -0.69 % [ -7.5 mmol/mol ] , P < 0.0001 ; -33.5 mg/dL [ -1.86 mmol/L ] , P < 0.0001 , respectively ) .